Efficacy of hemostatic gel for perioperative bleeding and prevention of delayed bleeding of cold snare polypectomy under anticoagulant

Naohisa Yoshida,Osamu Dohi,Yoshikazu Inagaki,Yuri Tomita,Hikaru Hashimoto,Reo Kobayashi,Ken Inoue,Ryohei Hirose,Yasutaka Morimoto,Yutaka Inada,Takaaki Murakami,Yoshito Itoh
DOI: https://doi.org/10.1002/jgh3.13029
2024-01-21
JGH Open
Abstract:In this study, we analyzed 122 cases with colorectal cold snare polypectomy (CSP) with continuous anticoagulant (91 cases: direct oral anticoagulant, 31 cases: warfarin) treated with a hemostatic gel, PuraStat. The rates of successful hemostasis and delayed bleeding were 92.6% and 0.0%, respectively. The rate of clipping after CSP was reduced to 7.4%. Background and Aim A hemostatic gel, PuraStat (3‐D Matrix, Tokyo, Japan), is used for various gastrointestinal hemostasis. In this study, we analyzed the efficacy of PuraStat for perioperative bleeding (POB) and prevention of delayed bleeding (DB) to colorectal cold snare polypectomy (CSP) with continuous anticoagulant. Methods This was a single‐center, retrospective study. Subjects were lesions of 2–9 mm under continuous anticoagulant from 2021 to 2023 and treated with PuraStat for POB. The definition of POB was bleeding which did not stop spontaneously by 1.0–1.5 min after resection and needed hemostasis. Successful hemostasis was defined as cessation of bleeding within 1.0–1.5 min after spraying PuraStat and the rate of it and risk factors of POB were analyzed. For comparison, cases receiving previous CSP without PuraStat were extracted from all cases with CSP (2018‐2021), and POB and DB rate (DBR) were analyzed after propensity score matching. Results One hundred twenty‐two lesions (91: direct oral anticoagulant (DOAC), 31: warfarin) with anticoagulant were analyzed and the rate of successful hemostasis with PuraStat was 92.6% (DOAC/warfarin: 93.4%/80.6%, P = 0.01). The rate of DB was 0.0%. Multivariate analysis showed that significant risk factors about unsuccessful hemostasis for POB with PuraStat were lesion size 8–9 mm (P
What problem does this paper attempt to address?